PCSK9 and atherosclerosis: Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, as newlipid-lowering drugs, can rapidly and substantially reduce LDL-C levels.Evolocumab has been demonstrated to significantly lower major cardiovascularevents in subjects with stable atherosclerotic cardiovascular disease (ASCVD) inthe secondary prevention setting [14, 15, 16].